AZN.UK

11,322

+0.34%↑

GSK

1,476

+0.34%↑

HLN.UK

343.7

+0.15%↑

STJ

1,248.5

+0.36%↑

HIK

1,617

-0.25%↓

AZN.UK

11,322

+0.34%↑

GSK

1,476

+0.34%↑

HLN.UK

343.7

+0.15%↑

STJ

1,248.5

+0.36%↑

HIK

1,617

-0.25%↓

AZN.UK

11,322

+0.34%↑

GSK

1,476

+0.34%↑

HLN.UK

343.7

+0.15%↑

STJ

1,248.5

+0.36%↑

HIK

1,617

-0.25%↓

AZN.UK

11,322

+0.34%↑

GSK

1,476

+0.34%↑

HLN.UK

343.7

+0.15%↑

STJ

1,248.5

+0.36%↑

HIK

1,617

-0.25%↓

AZN.UK

11,322

+0.34%↑

GSK

1,476

+0.34%↑

HLN.UK

343.7

+0.15%↑

STJ

1,248.5

+0.36%↑

HIK

1,617

-0.25%↓

Search

Oxford Biomedica PLC

Abierto

588 1.2

Resumen

Variación precio

24h

Actual

Mínimo

565

Máximo

593

Métricas clave

By Trading Economics

Ingresos

-11M

Ventas

78M

BPA

-0.11

Margen de beneficios

-13.726

Empleados

850

EBITDA

5M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+6.6% upside

Dividendos

By Dow Jones

Próximas Ganancias

23 sept 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

740M

Apertura anterior

586.8

Cierre anterior

588

Oxford Biomedica PLC Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

17 sept 2025, 23:01 UTC

Adquisiciones, fusiones, absorciones

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 sept 2025, 22:48 UTC

Adquisiciones, fusiones, absorciones

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 sept 2025, 21:59 UTC

Ganancias

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 sept 2025, 23:44 UTC

Charlas de Mercado

Nikkei May Rise as Yen Weakens -- Market Talk

17 sept 2025, 23:39 UTC

Charlas de Mercado

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 sept 2025, 22:20 UTC

Adquisiciones, fusiones, absorciones

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 sept 2025, 22:20 UTC

Adquisiciones, fusiones, absorciones

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 sept 2025, 22:20 UTC

Adquisiciones, fusiones, absorciones

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 sept 2025, 22:19 UTC

Adquisiciones, fusiones, absorciones

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 sept 2025, 22:18 UTC

Adquisiciones, fusiones, absorciones

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 sept 2025, 21:00 UTC

Ganancias

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 sept 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

17 sept 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 sept 2025, 19:59 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 sept 2025, 19:59 UTC

Charlas de Mercado

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 sept 2025, 19:07 UTC

Charlas de Mercado

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 sept 2025, 18:43 UTC

Charlas de Mercado

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 sept 2025, 18:38 UTC

Charlas de Mercado

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 sept 2025, 18:20 UTC

Charlas de Mercado

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 sept 2025, 18:18 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 sept 2025, 18:18 UTC

Charlas de Mercado

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 sept 2025, 18:14 UTC

Charlas de Mercado

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 sept 2025, 17:59 UTC

Charlas de Mercado

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 sept 2025, 17:15 UTC

Adquisiciones, fusiones, absorciones

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 sept 2025, 17:06 UTC

Adquisiciones, fusiones, absorciones

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 sept 2025, 16:51 UTC

Ganancias

Correct: Exor 1H Net Loss -EUR624M

17 sept 2025, 16:34 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 sept 2025, 16:34 UTC

Charlas de Mercado

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 sept 2025, 16:25 UTC

Ganancias

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 sept 2025, 16:23 UTC

Ganancias

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Comparación entre iguales

Cambio de precio

Oxford Biomedica PLC previsión

Precio Objetivo

By TipRanks

6.6% repunte

Estimación a 12 Meses

Media 617.207 GBX  6.6%

Máximo 930 GBX

Mínimo 400 GBX

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Oxford Biomedica PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

3

Comprar

1

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Oxford Biomedica PLC

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.
help-icon Live chat